(4Z,7Z,10Z,13Z,16Z,19Z)-21-fluorohenicosa-4,7,10,13,16,19-hexaenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (4Z,7Z,10Z,13Z,16Z,19Z)-21-fluorohenicosa-4,7,10,13,16,19-hexaenoic acid
• 化学式: C₂₁H₂₉FO₂
• 分子量: 332.5
• InChiKey: PWANWKRAWNCZPF-WKDYPCKZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  24
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] COMBINATION THERAPIES COMPRISING METFORMIN SALTS AND ANTIHYPERGLYCEMIA AGENTS OR ANTIHYPERLIPIDEMIA AGENTS<br/>[FR] THÉRAPIES COMBINÉES COMPRENANT DES SELS DE METFORMINE ET DES AGENTS ANTIHYPERGLYCÉMIE OU DES AGENTS ANTIHYPERLIPIDÉMIE
  申请人：THETIS PHARMACEUTICALS LLC

  公开号：WO2014008374A2

  公开（公告）日：2014-01-09

  The present invention is directed to a combination therapy comprising metformin eicosapentaenoate or metformin docosahexaenoate, or a mixture thereof, and an antihyperglycemic agent or an antihyperlipidemic agent, or a pharmaceutically-acceptable salt or prodrug thereof, or a pharmaceutically-acceptable salt of said prodrug. The invention further relates to methods of treating a metabolic disorder selected from the group consisting of type 2 diabetes (T2D), pre-diabetes, obesity, metabolic syndrome, hypertrilipidemia and T2D complications such as neuropathy, nephropathy, retinopathy, cataracts and cardiovascular complications, including cardiac arrhythmia, myocardial infarction, stroke, and cardiomyopathy in diabetic patients.